Histone lysine demethylases as targets for anticancer therapy

• Published in: Nature reviews. Drug discovery Vol. 12; no. 12; pp. 917 - 930
• Main Authors: Højfeldt, Jonas W., Agger, Karl, Helin, Kristian
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 01.12.2013; Nature Publishing Group
• Subjects: 631/154; 631/208/176; 631/67; Animals; Antimitotic agents; Antineoplastic agents; Antineoplastic Agents - administration & dosage; Biomedicine; Biotechnology; Cancer; Cancer Research; Drug Delivery Systems - methods; Drug therapy; Enzymes; Health aspects; Histone Deacetylase Inhibitors - administration & dosage; Histone Deacetylase Inhibitors - chemistry; Histone Demethylases - antagonists & inhibitors; Histone Demethylases - chemistry; Histone Demethylases - metabolism; Humans; Medicinal Chemistry; Molecular Medicine; Neoplasms - drug therapy; Neoplasms - enzymology; Pharmacology/Toxicology; Physiological aspects; review-article; Denmark

Key Points There is strong evidence that members of the histone lysine demethylase families are causally linked to cancer and they are therefore considered as potential targets for small-molecule therapeutics. Lysine-specific demethylase 1 (LSD1) is required for the maintenance of acute myeloid leuk...